Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1221-1231

  Fujisawa, Toshio ^a   Nakashima, Hideyuki ^a   Nakajima, Atsushi ^b   Joshi, Bharat H ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

gemcitabine; IL 13R 2; interleukin 13 cytotoxin; orthotopic mice model; pancreatic ductal adenocarcinoma

Indexed keywords

CINTREDEKIN BESUDOTOX; GEMCITABINE; INTERLEUKIN 13 RECEPTOR ALPHA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOLUS INJECTION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL TIME; TUMOR VOLUME; WHOLE BODY IMAGING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650719519     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25437     Document Type: Article

References (38)

1. Cartwright T, Richards DA, Boehm KA,. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 2008; 15: 308-13.
2. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
3. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-7. (Pubitemid 46954645)
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
5. Joshi BH, Plautz GE, Puri RK,. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000; 60: 1168-72.
6. Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK,. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003; 9: 6381-8.
7. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W,. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996; 87: 4333-9.
8. Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK,. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997; 3: 151-6.
9. O'Shea JJ, Gadina M, Schreiber RD,. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109 (Suppl): S121-31.
10. Kawakami K, Taguchi J, Murata T, Puri RK,. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001; 97: 2673-9.
11. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A,. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
12. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK,. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010; 16: 577-86.
13. Fujisawa T, Joshi B, Nakajima A, Puri RK,. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009; 69: 8678-85.
14. Debinski W, Obiri NI, Pastan I, Puri RK,. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995; 270: 16775-80.
15. Kioi M, Kawakami K, Puri RK,. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 2004; 10: 6231-8.
16. Husain SR, Joshi BH, Puri RK,. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001; 92: 168-75.
17. Kawakami K, Kawakami M, Joshi BH, Puri RK,. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001; 61: 6194-200.
18. Kawakami M, Kawakami K, Puri RK,. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002; 1: 999-1007.
19. Vallera DA, Stish BJ, Shu Y, Chen H, Saluja A, Buchsbaum DJ, Vickers SM,. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 2008; 57: 634-41.
20. Joshi BH, Kawakami K, Leland P, Puri RK,. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002; 8: 1948-56.
21. Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK,. Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. J Neurooncol 2008; 10: 265-74.
22. Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK,. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res 2007; 67: 9903-12.
23. Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK,. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer 2009; 124: 1440-8.
24. Symon Z, Davis M, McGinn CJ, Zalupski MM, Lawrence TS,. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 2002; 53: 140-5.
25. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, Danesi R,. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 2005; 93: 319-30.
26. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK,. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006; 66: 981-8.
27. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-52.
28. Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008; 9: 39-44.
29. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL,. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-83.
30. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, de Jager RL, Eckhardt SG, O'Reilly EM,. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 4441-7.
31. O'Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM, Blattler WA,. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995; 86: 4286-94.
32. Kim CN, Bhalla K, Kreitman RJ, Willingham MC, Hall P, Tagge EP, Jia T, Frankel AE,. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res 1999; 23: 527-38.
33. Polito L, Bolognesi A, Tazzari PL, Farini V, Lubelli C, Zinzani PL, Ricci F, Stirpe F,. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 2004; 18: 1215-22.
34. Lee CJ, Dosch J, Simeone DM,. Pancreatic cancer stem cells. J Clin Oncol 2008; 26: 2806-12.
35. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8. (Pubitemid 36418143)
36. Hong SP, Wen J, Bang S, Park S, Song SY,. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009; 125: 2323-31.
37. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007; 25: 837-44.
38. Kuzel T, Smith J, II, Urba W, Fox B, Moudgil T, Strauss L, Joshi BH, Puri RK,. IL13-PE38QQR cytototxind in advanced renal cell carcinoma (RCC): phase 1 and pharmacokinetic study. San Francisco, CA: American Society of Clinical Oncology (ASCO), 2002.